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Abstract
Increased CCL5 levels are markers of an unfavourable outcome in patients with melanoma, breast, cervical, prostate, gastric
or pancreatic cancer. Here, we have assessed the role played by CCL5/CCR5 interactions in the development of colon
cancer. To do so, we have examined a number of human colorectal carcinoma clinical specimens and found CCL5 and its
receptors over-expressed within primary as well as liver and pulmonary metastases of patients compared to healthy tissues.
In vitro, CCL5 increased the growth and migratory responses of colon cancer cells from both human and mouse origins. In
addition, systemic treatment of mice with CCL5-directed antibodies reduced the extent of development of subcutaneous
colon tumors, of liver metastases and of peritoneal carcinosis. Consistently, we found increased numbers of CD45-
immunoreactive cells within the stroma of the remaining lesions as well as at the interface with the healthy tissue. In
contrast, selective targeting of CCR5 through administration of TAK-779, a CCR5 antagonist, only partially compromised
colon cancer progression. Furthermore, CCL5 neutralization rendered the tumors more sensitive to a PDGFRb-directed
strategy in mice, this combination regimen offering the greatest protection against liver metastases and suppressing
macroscopic peritoneal carcinosis. Collectively, our data demonstrate the involvement of CCL5 in the pathogenesis of
colorectal carcinoma and point to its potential value as a therapeutic target.
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Introduction
Tumor-stroma interactions are recognized as critical compo-
nents of tumor invasion and metastatic potential of colon
carcinoma [1]. Stromal, inflammatory and cancer cells commu-
nicate among themselves directly through cell contact but also
indirectly through paracrine signals [2,3]. Such signals favor
tumor development in multiple ways: they act as growth factors,
stimulate angiogenesis, modulate the extracellular matrix, induce
the recruitment of additional stromal cells and take part in
immune evasion mechanisms of cancer. As a consequence,
identification of tumor-promoting factors for cancer therapeutics
has become of major interest to devise anti-tumor strategies to be
applied either as single-agent treatment or as combination therapy
in case where tumors fail to respond to monotherapy. Various
factors have been identified so far as promoters of colon cancer
progression, most common of which are the VEGF (vascular
endothelial growth factor) family, the FGF (fibroblast growth
factor) family and the PDGF (platelet-derived growth factor)
family, their production within the neoplasm correlating with
tumor grade and shorter patient survival [4–8]. More recently,
there has been increasing evidence from various studies including
ours that the chemokines produced within the tumor microenvi-
ronment may also play a crucial role in the pathogenesis of CRC
(colorectal carcinoma) [9–12].
Among the chemokines thought to strongly promote carcino-
genesis and stromagenesis is CCL5/RANTES (CC chemokine
ligand 5/Regulated upon activation, normal T-cell-expressed and
secreted) which was initially described for its key role in
inflammatory diseases. Indeed, clinical evidence has revealed that
elevated levels of tissue or plasma CCL5 are markers of an
unfavourable outcome in patients with either melanoma, breast,
cervical, prostate, gastric or pancreatic cancer [13–20]. In breast
cancer, in vivo CCL5 neutralization or CCR5 antagonism were
shown to abrogate the MSC-induced metastasis of cancer cells
thus implicating CCL5/CCR5 as a key axis in this malignancy
[21]. Selective targeting of the CCR5/CCL5 signaling also led to
reduced tumor growth in experimental pancreatic adenocarcino-
ma through disruption of CCR5-dependent recruitment of
regulatory T cells into tumors [22]. Anibamine, a new CCR5
antagonist also suppressed the invasive and metastatic properties
of prostate cancer cells in mice [23]. Finally, CCL5 blockade
significantly compromised gastric cancer progression [20]. Inter-
estingly, CCL5 has recently been reported to be expressed in
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primary tumors [24]. Based on the aforementioned clinical
observations in several cancers, it is tempting to speculate that
CCL5 and its receptors may have a substantial role in CRC
progression and may thus represent an interesting target for the
treatment of this malignancy. To date, however, none of these
aspects have been addressed in vivo.
The study described herein aimed precisely at getting new
insights into the role played by CCL5/CCR5 interactions in the
development of colorectal carcinoma. To do so, we have
examined a number of human colon cancer clinical specimens
and found CCL5 and its receptors over-expressed within primary
as well as liver and pulmonary metastases of CRC patients
compared to healthy tissues. To assess the relevance of CCL5/
CCR5 neutralization in colon carcinoma, we have used syngeneic
experimental models of orthotopic (liver) and ectopic (subcutis)
colon cancer in immunocompetent mice. We have examined the
effect of CCL5- or CCR5-blockers administered as single agents or
in combination with a murine PDGFRb-directed treatment, this
strategy being currently under clinical evaluation for the treatment
of CRC cancers. This report provides the first preclinical evidence
for a role of CCL5 in colon carcinoma and demonstrates that
CCL5 blockade has the potential to reduce colon cancer
progression and to improve the therapeutic response in multidrug
regimen.
Materials and Methods
Reagent
The following reagent (TAK-779) was obtained through the
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, National Institute of Allergy and Infectious Diseases,
NIH.
Tumor Cell lines and Experimental Animals
Human HT29 and mouse CT26 colon carcinoma cells were
purchased from ATCC and maintained in DMEM medium
supplemented with 10% heat-inactivated FBS as previously
described [11]. Female SCID and BALB/c mice, 6 to 8 weeks
old, were purchased from Harlan (Gannat, France).
Ethics
Ten sets of primary colon cancer tumors and metastatic tissues
from the same patients as well as paired ‘‘healthy’’ colonic biopsies
were collected from patients with invasive adenocarcinomas, who
underwent surgical biopsies or initial surgery at the Institut Paoli-
Calmettes (IPC, Marseille, France) between 1987 and 2007. Each
patient gave written informed consent and the study was approved
by the IPC ‘‘Comite ´ d’Orientation Strate ´gique’’. All of the
procedures involving laboratory animals and their care were
approved by institutional review board (Permit number # A06-
088-14).
TaqMan real-time PCR experiments
Total RNA from human colorectal cancer and healthy colon, from
mouse healthy and tumor tissues as well as colon carcinoma cell lines
was extracted using RNeasy kit (Qiagen, Courtaboeuf, France) and
transcribed into cDNA using the Superscript III enzyme (Invitrogen,
Cergy Pontoise, France) as previously described [11]. Real-time PCR
was performed in an ABI PRISM 7900HT and carried out using
TaqManH gene expression assays for human samples (hCCR1: Hs
00174298m1, hCCR3: Hs 00356601m1, hCCR5 Hs 00152917m1,
hCCL5:Hs00174575m1)(AppliedBiosystem,Courtaboeuf,France),
or SYBRH gene expression assays according to the manufacturer’s
instructions (Applied Biosystem). The primer sequences for mouse
CCL5 were: forward, 59- TGCCCACGTCAAGGAGTATTTC-39;
and reverse, 59- AACCCACTTCTTCTCTGGGTTG-39,f o r
mouse CCR1: forward, 59- AGGCCCAGTGGGAGTTCAC-39;
and reverse, 59- TCTTCCACTGCTTCAGGCTCTT-39,f o r
mouse CCR3: forward, 59- AAGCTTTGAGACCACACCC-
TATG-39; and reverse, 59- GACCCCAGCTCTTTGATTCTGA-
39; for mouse CCR5, forward 59- TTATCTCTCAGTGTTC-
TTCCGAAAAC-39 and reverse, 59- TTCTCCTGTGGAT-
CGGGTATAGA-39. Relative levels in mRNA expression were
determined using DCT values obtained by subtracting CT control
(human or mouse actin) from CT target gene measured in the same
RNA preparation. Comparative level of mRNA expression between
healthy (X) and metastatic tissues (Y) was calculated using the formula
DCTY – DCTX and expressed as fold over healthy (2DDCT). Murine
healthy colon tissues were used to analyse mouse tumors and human
healthy colon specimens were used to analyse human tumors and
HT-29 samples.
In vitro proliferation assay
Briefly, colon cancer cells pretreated or not with TAK-779 or
anti-CCL5 antibodies (at the indicated concentrations) were
seeded at a density of 10
4 cells/cm
2 and incubated either in
serum-enriched medium or in base medium (containing 0.1%
Bovine Serum Albumin) supplemented or not with various
concentrations of recombinant CCL5 (Peprotech, Neuilly sur
Seine, France) for 5 days before being trypsin-detached, collected
and enumerated as previously described [11].
In vitro chemotaxis assay
Chemotactic responses of colon cancer cells were evaluated by
using 24-well chemotaxis chambers and polyethylene terephtalate
inserts with 8 mm pores (Becton Dickinson, San Jose, CA) coated
with 6.5 mg/mL fibronectin (Sigma, Lyon, France) or with 50 mg/
mL collagen (Becton Dickinson) for the CT26 cells or the HT29
cells, respectively [11]. Colon cancer cells, pretreated or not with
TAK-779 or anti-CCL5 antibodies (at the indicated concentra-
tions), were placed in the upper well (5610
4 cells) and various
concentrations of recombinant CCL5 (Peprotech) were added to
the lower wells. After incubation of the plates for 18 hours (CT26
cells) or for 40 hours (HT29 cells) at 37uCi n5 %C O 2 atmosphere,
non-migrated cells were removed from the upper well and the
migrated cells collected on the lower side of the insert were stained
using crystal violet dye and enumerated. Migration index was
calculated as the ratio of the number of migrated cells in
chemoattractant-containing wells divided by the number of cells
that migrated to base medium alone.
PDGFRb gene expression vector
DNA encoding mPDGFRb was cloned and inserted into the
pTOPO-cDNA3 eukaryotic expression vector (Invitrogen). Iden-
tities of sense (pcDNA3-PDGFRb) and antisense (control vector)
products were confirmed by sequencing.
Plasmid preparation and formulation
The DNA vaccine plasmid (pcDNA3-PDGFRb) and the
corresponding control vector were used as antigens. All plasmids
were purified using EndoFree plasmid purification columns
(Qiagen) and were confirmed to be free of endotoxin contamina-
tion (endotoxin ,0.1 EU/mg plasmid DNA) by the Limulus
amoebocyte lysate assay (Lonza, Le Perray en Yvelines, France).
The tetrafunctionalized amphiphilic block copolymer 704 (MW
5,500) was supplied by In-Cell-Art (Nantes, France). Stock
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Formulations of DNA with 704 (final concentration 0.3%) were
prepared immediately prior to intramuscular injection by
equivolumetric mixing of copolymers in water with plasmid
DNA solution as previously described [25,26]. DNA doses
administered are indicated throughout the study.
Transfection with PDGFRb gene expression vector
The correct expression of mPDGFRb was verified by transient
transfection of CHO cells with the control vector and the DNA
vaccine plasmid (pcDNA3-PDGFRb) using AMAXA Biosystems
(Lonza). Twenty-four hours post-transfection, cell lysates from
CHO cells were prepared as previously described [27] before
being subjected to SDS-PAGE. Western blotting was performed
either with goat anti-mouse PDGFRb antibodies (Santa Cruz
Biotechnology, Le Perray-en-Yvelines, France) or with diluted
serum obtained from the PDGFRb-vaccinated- mice. Detection
was done either by rabbit anti-goat Abs- or by goat-anti mouse
Abs- conjugated to horseradish peroxidase (Dako, Trappes,
France). Bands were visualized by chemiluminescence-enhanced
reaction (Amersham, Les Ulis, France).
Mouse models
Subcutaneous, liver and pulmonary metastasis
models. For the induction of subcutaneous and hepatic
tumors, CT26 cells (5610
4) or HT29 cells (3610
6) were injected
in the flank or under the liver capsule of BALB/c or SCID mice,
respectively. For the induction of pulmonary metastases, CT26
cells (3610
4) or HT29 cells (2610
6) were delivered by intravenous
tail injection into BALB/c or SCID mice, respectively. At
sacrifice, complete post-mortem examinations were performed.
Subcutaneous and hepatic tumors were excised, weighed and
measured with callipers in the two perpendicular axes (a and b).
Tumour volume was calculated according to the formula ab
2p/6.
Intramuscular DNA vaccination. Following a prophylactic
setting, anesthetized mice were vaccinated 3 times at 3-week
interval (days 0, 21 and 42) by intramuscular injections of DNA-
polymer formulations into both tibialis anterior muscles as previously
described [25,26]. Three weeks after the last boost (day 66), mice
were challenged by injection of 5610
4 CT26 murine colon
carcinoma cells under the liver capsule.
Mouse treatments. Anti-CCL5 or control isotype IgG
antibodies (32 mg per mouse, Peprotech) were injected into the
peritoneum of BALB/c mice 72 h after tumor implantation and
twice weekly for the duration of the experiments (from day 69 to
87). TAK-779, the small-molecule CC chemokine receptor 5
(CCR5) inhibitor [28,29] was injected into mice (150 mg/mouse)
72 h after tumor cells inoculation and daily thereafter until
sacrifice (from day 69 to 87).
At sacrifice (day 87), hepatic tumors were excised and weighed.
Incidence of peritoneal carcinosis into mice was expressed as
percent of carcinosis-bearing animals in each group.
Determination of serum levels of mPDGFRb-specific Abs
by ELISA
Serum was collected by retro-orbital bleeds at different time
points after vaccination from immunized mice. ELISA plates were
coated with 2 mg/ml anti-mouse PDGFRb antibodies (Santa
Cruz) in 100 ml PBS overnight at 4uC. The next morning, the
plates were washed twice with PBS/Tween 20 (PBST), saturated
for 30 minutes with phosphate buffer containing 1% skim milk
and 0.12% Triton X-100 (assay buffer), washed again twice before
being incubated for 18 h at room temperature with recombinant
mouse PDGFRb. After repeated washes, serial dilutions of serum
samples from immunized mice were added to the well in
duplicates. The plates were further incubated for 2 h, washed
four times with PBST, and bound-enzyme activity was revealed
with a chromogenic OPD substrate solution and measured at
490 nm.
Histology/Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of colon cancer
metastatic tissues were stained with haematoxylin/eosin for
morphologic evaluation. Immunostaining of CD45 was performed
with anti-mouse CD45 mAb (BD Pharmingen, Le Pont de Claix,
France) by the avidin-biotin complex immunoperoxidase method
following microwave antigen retrieval. The primary antibody was
replaced with isotype-matched antibodies in adjacent tissue
sections as negative control. Expression of CD45 in mouse spleen
was used as positive control.
Statistical analysis
Results are expressed as mean 6 s.e.m. and analyzed using the
unpaired Student’s t test or the Kruskal-Wallis test for multiple
comparisons.
Results
Expression of CCL5 and its cognate receptors in the
resected colorectal carcinoma specimens
We analysed by quantitative RT-PCR (real time-quantitative
reverse transcription polymerase chain reaction) the expression
levels of human CCL5 and its receptors CCR1, CCR3 and CCR5
on surgical resection pieces of human primary colon tumors, of
paired hepatic and pulmonary colorectal cancer metastases and of
corresponding healthy tissues collected from the same patients. We
observed increased levels of CCL5 expression in colorectal tumors
(6 fold, P,0.05), liver metastases (8.5 fold, P,0.05) and lung
metastases (4 fold, P,0.05) compared to healthy specimens
(Figure 1A, Table S1). Because CCL5 acts through specific
receptors, we also looked for such receptors that were expressed
within tumor and metastatic specimens. Distinct patterns of CCRs
expression were measured according to the target organ. Whereas
CCR1 and CCR5 were both found to be significantly overex-
pressed in malignant liver and lung tissues compared to
corresponding control biopsies (P,0.01 in liver, P,0.05 in lungs),
CCR3 was only found significantly overexpressed within primary
colorectal tumors compared to healthy organs (P,0.05)
(Figure 1A, Table S1).
In order to further assess the role of the CCL5/receptors axis in
colon cancer, we have looked for a relevant mouse colon
carcinoma model. To do so, we have analysed by quantitative
RT-PCR the expression level of CCL5/CCRs in the human
HT29 and in the mouse CT26 colon cancer cells grown in culture.
We observed CCL5 and CCR5 expression by both cell lines in
vitro (Table S1). None of the two other CCL5 receptors (CCR1
and CCR3) were detected in the HT29 cells whereas CCR1
expression was found in the CT26 cells. To analyse whether the
expression patterns of CCL5/receptors within malignant tissues
were in accordance with those observed in human biopsies, we
next developed experimental models of orthotopic (liver and lung
metastases) and ectopic (subcutis) colon cancer in immunocompe-
tent and immunodeficient mice. Colon cancer cells of mouse
(CT26) or human (HT29) origins were inoculated into mice either
subcutaneously, under the liver capsule or through tail vein
injection to generate pulmonary metastases. At sacrifice, levels of
chemokines/receptors within the distinct target organs were
evaluated by real-time quantitative PCR using murine primers
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xenografts (Figure 1B and C). Elevated levels of CCL5 expression
were detected in all tumor models (subcutaneous, hepatic and
lung) developed with mouse CT26 cells and with human HT29
cells except in pulmonary lesions derived from CT26 cells. In
contrast, the patterns of expression of CCL5 receptors were
complex and changed when cells were grown in vivo compared to
culture conditions. None of the two tumor models (CT26 and
HT29) exactly reflected the pattern of chemokine receptors
expression observed in the human biopsies. Therefore, based on
the fact that all three CT26 tumor types (subcutaneous, liver and
lung) expressed both CCL5 and CCR5 in vivo, whereas HT29
xenografts exhibited levels of CCR5 below the threshold of
detection of the PCR technique, we have found more appropriate
to work with the CT26 models to assess the role played by CCL5/
CCR5 interaction in colorectal carcinoma. In addition, the CT26
syngeneic model that is developed into immunocompetent mice
also appeared the most appropriate to take into account CCL5/
CCR5-dependent immune mechanisms especially considering that
our ultimate goal was to combine CCL5 blockade with a vaccine
strategy.
CCL5 enhances CRC cell proliferation and migration in
vitro
The expression of CCL5 receptors by human and murine
colon carcinoma cells has led us to determine the ability of their
common ligand CCL5 to stimulate their proliferation and
migration in vitro. To this end, we examined and quantified cell
growth after plating CT26 and HT29 cells for 5 days at low
density in base medium alone or supplemented with various
concentrations of CCL5. Within 5 days of serum starvation, we
observed that CRC cells of both origins proliferate in response to
CCL5 treatment in a dose-dependent manner (Figure 2A and C).
The maximum growth was observed in response to 50 ng/ml
CCL5. We next assessed the ability of the CRC cells to migrate
in response to CCL5. CT26 and HT29 cells were harvested,
placed into modified Boyden chambers and allowed to migrate
towards various concentrations of CCL5. Figure 2B and D shows
that CRC cells migrated to the chemokine compared with base
medium alone. Given the key role played by CCR5 in mediating
CCL5 actions in various cancer cells, we next attempted to
disrupt the CCL5/CCR5 action using TAK-779, a non-peptide
CCR5 antagonist previously described to impair tumor devel-
opment in pancreatic cancer [22]. Increasing doses of TAK-779
(ranging from 10 to 500 nM) were tested on the CT26 cells
according to IC50 values described in the low nM range [28,29].
We observed a dose-dependent effect of TAK-779 on both the
growth and the migratory responses of the CRC cells, as
depicted on Figure 2E and F. The strongest inhibition was
obtained with 200 nM TAK-779, higher doses leading to
cytotoxic effects on the cells. However, only 28% of the CRC
responses were abrogated by CCR5 blockade, thus suggesting
the involvement of CCR5-independent mechanisms in both
cellular processes. Various concentrations of anti-CCL5 antibod-
ies, ranging from 3 to 30 mg/ml, were then applied to CT26
cells. As shown on Figure 2G and H, CCL5 neutralization
obtained with the 10 mg/ml dose of antibodies totally impaired
CRC cells migratory and growth responses to the chemokine.
Collectively, these data suggest that CCL5/receptors activation
appears as a common feature of the CRC cells from distinct
origins and that it could mediate the malignancy-related
properties of colon cancer cells.
CCL5-CCRs interactions are involved in colon cancer
development
To probe whether the malignancy-related properties of CCL5
exerted onto colon cancer cells in vitro also have a relevance in vivo,
we evaluated the impact of CCL5 neutralization on the
Figure 1. Expression of CCL5 and its corresponding CCR1,
CCR3, CCR5 receptors in human biopsies and mouse tissues of
colorectal carcinoma. Analysis of levels of expression of human (h) or
mouse (m) targets was performed by quantitative RT-PCR in surgical
resection pieces of human colorectal carcinoma (n=10) (A), in
experimental subcutaneous tumors (n=6), liver (n=6) and lung
metastases (n=6) derived from mouse CT26 cells (B) or derived from
human HT29 cells (C) compared with corresponding healthy tissues
(normal human, n=10, and normal mouse colon, n=6, respectively).
The relative levels of expression were calculated using standard curves
and expressed as 1/DCt. DCt values were calculated by substracting Ct
of normalizing gene from Ct of target gene, measured in the same RNA
preparation. Comparative level of mRNA expression between healthy
(X) and metastatic tissues (Y) was calculated using the formula DCTY –
DCTX and expressed as fold over healthy (2DDCT). Black bars: primary or
subcutaneous colon tumors; hatched bars: liver metastases; dotted
bars: lung metastases. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0028842.g001
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into immunocompetent Balb/c mice. At day 0, mice were
challenged with a subcutaneous injection of CT26 cells under
the skin. Animals were then treated on days +7, +10, +14 and +18
with intratumor administrations of anti-CCL5 or control isotype
IgG antibodies. At sacrifice, the extent of tumor development was
assessed by measuring the tumor burdens. CT26-challenged mice
developed within 7 days a palpable tumor averaging 20 mm
3 that
grew to a size of ,336 mm
3 by day 21 (Figure 3A). In contrast, the
anti-CCL5-treated mice developed tumors that grew with a
Figure 2. CCL5-induced tumor-promoting properties in CRC cells. (A, C, E, G) Proliferation of the CT26 and HT29 cells was assessed in
response to a 5-day treatment with base medium alone (BSA, open bars), with serum-enriched medium (FBS, hatched bars) or with the indicated
concentrations of recombinant CCL5 (filled bars), in the presence or in the absence of TAK-779 or anti-CCL5 antibodies (at the indicated
concentrations). (B, D, F, H) CRC cells were assayed for chemotaxis in response to base medium alone (BSA, open bars), to serum-enriched medium
(FBS, hatched bars) or to the indicated concentrations of recombinant CCL5 (filled bars), in the presence or in the absence of TAK-779 or anti-CCL5
antibodies. Results represent the mean6s.e.m. of six determinations. * p,0.05, ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0028842.g002
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clearly detectable after the third anti-CCL5 treatment (40%
reduction, P,0.01). At sacrifice, their volume reached an average
size of 202 mm
3, corresponding to a 40% reduction compared to
control burdens (P,0.05).
Given that liver is a major target organ in the CRC malignancy
and that the highest expression levels of CCL5, CCR1 and CCR5
were found within liver metastases of human colon cancer
patients, we next sought to assess the protective potential of the
anti-CCL5 treatment on the development of experimental hepatic
metastases into immunocompetent mice. Animals were thus
challenged with an injection of CT26 cells under the liver capsule
before being treated 72 hours after inoculation and twice weekly
for the duration of the experiment with intraperitoneal adminis-
trations of anti-CCL5 antibodies at the dose previously shown to
be effective [20,21]. Although 100% of the mice from both groups
developed liver tumors, there was a significant reduction (30%) in
the overall tumor load in the livers of the anti-CCL5-treated mice
compared to the control group, as assessed by measuring liver
weight (1.24 vs 1.78, P,0.05) (Figure 3B).
Besides liver tumors, we also observed differences in the extent
of macrospcopic peritoneal carcinosis between the two groups of
treatments (Figure 3C). Whereas peritoneal dissemination was
found in 100% of the control mice, it was only observed in 40% of
those treated with the anti-CCL5 antibodies.
mPDGFRb vaccination reduces growth of CT26 colon
carcinoma metastases
Given that the anti-CCL5 strategy could only lead to a
moderate therapeutic effect against colon cancer, we next sought
Figure 3. Protective effect of CCL5 neutralization on the development of colorectal tumors, metastases and peritoneal carcinosis.
(A) Mice subcutaneously-challenged with CT26 cells received four intratumor injections of anti-CCL5 (open dots) or isotype-matched antibodies (filled
dots) at the indicated times. Upon sacrifice, the extent of tumor development was assessed by measuring the tumor burdens. (B) Incidence and
extent of tumor development within livers of CT26-challenged mice treated with anti-CCL5- or isotype-matched antibodies. (C) Incidence of
peritoneal carcinosis expressed as percent of mice bearing carcinosis. (n=5/group). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0028842.g003
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combination with an anti-PDGFRb strategy. Indeed, the PDGF/
PDGFRb interaction is known to play a key role in the promotion
of several malignancies including colorectal carcinoma. In
particular, Wehler et al [30], have shown that PDGFRb
expression correlated with lymphatic dissemination in human
colorectal cancer. Working on 99 human CRC biopsies, the
authors reported by immunohistochemistry and RT-PCR that
PDGFRb expression occurred in 60% of the patients. Similarly,
PDGFRb expression was detected in four human CRC cell lines:
Caco-2, HT29, SW480 and SW620. Consistent with this, we
observed high levels of expression of mPDGFRb in CT26 derived
liver metastases (Figure 4A). As a consequence, we created a DNA
vaccine encoding mPDGFRb and verified the correct expression
of mPDGFRb by Western Blot analysis after transient transfection
of CHO cells (Figure 4B). We then prepared formulations of DNA
vaccine plasmids with 704, a tetrafunctionalized amphiphilic block
copolymer that has previously been shown to improve intramus-
cular DNA vaccination by simultaneously increasing transgene
expression and activating immunity [25,26]. The potency of 704-
formulated DNA vaccine plasmid to allow gene delivery into
tibialis anterior muscles of 6 weeks-old Balb/c mice was evaluated by
Western Blotting (Figure 4C) and confirmed muscular expression
of the protein following administration of low-dose DNA (25 mg).
According to a previously optimized immunization protocol
[25,26], mice were challenged on day 0, and restimulated on
day +21, and day +42 with the DNA vaccine (50 mg) or the control
vector formulated with 0.3% polymer 704. Two weeks after the
prime-boost immunization, sera from both groups of animals were
analysed for the presence of mPDGFRb specific antibodies. As
depicted on Figure 4D, immunized mice exhibited a humoral
response to mPDGFRb protein detected by ELISA (P=0.005).
The presence of specific mPDGFRb antibodies in their sera was
further confirmed by testing their ability to react with the band of
the purified antigen from the mPDGFRb-transfected CHO cells
by Western blot analysis (Figure 4E) and by reprobing the blot
with a commercial antibody specific to mPDGFRb. The ability of
our DNA-based vaccine to induce a mPDGFRb-specific adaptive
Figure 4. Formulation of DNA with 704 polymer increases mPDGFRb expression level after intramuscular injection and induces a
specific immune response. Western blot analyses of mPDGFRb expression level (A) in CT26-derived subcutaneous tumors, pulmonary and liver
metastases, (B) in pcDNA-3 control (with antisens PCR product) and pcDNA3-mPDGFRb-transfected CHO cells and (C) in tibialis anterior muscles of
Balb/c mice injected once with low-dose (25 mg) of mPDGFRb encoding plasmid formulated in 704 copolymer (n=4). (D) Determination of serum
levels of mPDGFRb-specific antibodies by ELISA. Mice were challenged on day 0, and restimulated on day +21, and day +42 with the DNA vaccine
(50 mg) or the control vector formulated with 0.3% 704 before being sacrificed two weeks later for serum collection (n=5). ** p,0.01. (E) Mouse sera
were assayed for their ability to react with the band of the purified antigen from the mPDGFRb-transfected CHO cells by Western blot analysis. Goat
anti-mPDGFRb antibodies from Santa Cruz were used for comparison.
doi:10.1371/journal.pone.0028842.g004
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protect CT26-challenged mice. Following a prophylactic setting,
we administered the mPDGFRb vaccine according to the prime-
boost regimen described above prior to inoculating the CT26 cells
under the liver capsule (Figure 5A). Twenty-one days after tumor
cell challenge, we compared the extent of tumor development
within livers from both the immunized and the control animals.
Although we observed a slight decrease (16%) in the tumor
burdens of the mice vaccinated against mPDGFRb compared to
those of the non-immunized ones (1.49 vs 1.8) this reduction was
not statistically significant (Figure 5B). In addition, the incidence of
peritoneal carcinosis in vaccinated mice remained of 100%
(Figure 5C).
CCL5 blockade potentiates the targeting of mPDGFRb in
CT26 challenged mice
We next evaluated the impact of combined strategies on
metastatic colon carcinoma. mPDGFRb-vaccinated mice were
thus challenged with CT26 cells before being treated with CCL5-
directed antibodies. Mice treated with such combined regimen
developed much smaller liver metastases compared to control
animals (1.07 vs 1.79 in controls, P,0.05) (Figures 5B). In
addition, vaccination allowed to increase the protective action of
CCL5 blockade from 30% to 40% and to reduce tumor incidence
from 100% to 60% in mice. Aside from reducing liver metastases,
combined CCL5- and mPDGFRb-directed strategies led to a
drastic decrease in the macroscopic peritoneal dissemination in
100% of the mice whereas all other regimen failed to significantly
impair carcinosis (Figure 5C).
In a next step, we attempted to disrupt CCL5 action using TAK-
779, a non-peptide CCR5 antagonist. We therefore performed the
systemic administration of TAK-779 into CT26-liver metastases
bearing mice as previously described in pancreatic cancer [22].
However, TAK-779 treatment did not significantly protect mice
from developing liver metastases (1.35 vs 1.79, P.0.05) and
peritoneal dissemination was of 100% in those mice. Although, no
significant difference was measured in the antitumor effect on the
liver between TAK-779 and anti-CCL5 Abs (1.35 vs 1.23, P.0.05),
there was a marked difference in the peritoneal carcinosis between
both groups (100% with TAK-779 vs 40% with anti-CCL5). In
addition, combining both treatments (anti-CCL5 Abs + TAK-779)
failed to increase further the efficacy of CCL5 neutralization thus
suggesting that blocking CCL5 action may recapitulate more
signaling pathways than simply that of CCR5. Finally, the
therapeutic efficacy of combining CCR5- and mPDGFRb-directed
strategies was much less than that of combining CCL5 Abs/vaccine
in terms of tumor load (1.2 vs 1.07), of tumor incidence (100% vs
60%) and of peritoneal dissemination (100% vs 0%) again
suggesting the superiority of CCL5 blockade + PDGFRb vaccine
over all other combinations (Figures 5 B and C).
Figure 5. Combining CCL5- and PDGFRb-directed strategies offers the greatest protection against liver tumors and peritoneal
carcinosis. (A) Mice were challenged on day 0, and restimulated on day +21, and day +42 with the DNA vaccine (50 mg) or the control vector
formulated with 0.3% poloxamine 704 before receiving three weeks later an injection of CT26 cells under the liver capsule. Seventy two hours later,
mice were treated with CCL5-directed antibodies or with TAK-779 or both, as described in the Materials and Methods section. (B) Incidence and
extent of tumor development within livers of CT26-challenged mice, immunized or not against PDGFRb and treated either with anti-CCL5 antibodies,
with TAK-779, or with both blockers. (C) Incidence of peritoneal carcinosis expressed as percent of mice bearing carcinosis. (n=5/group). * p,0.05,
** p,0.01.
doi:10.1371/journal.pone.0028842.g005
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anti-CCL5/PDGFRb–treated animals display increased
leukocytic infiltration
At a microscopic level, CT26 cells of control mice produced
voluminous tumors composed of cells growing in interlacing
bundles or sheets and displaying numerous mitotic figures.
Necrotic areas were prominent in the largest tumors (Figure 6A).
Livers from mice treated either with TAK-779, or with
mPDGFRb vaccine, or with both, displayed fewer nodules than
those of untreated animals and most of these lesions were smaller
in size (Figure 6 B, C and D). The most sizeable lesions resembled
CT26 control tumors with areas of necrosis and minimal
leukocytic infiltration. The surrounding parenchyma often dis-
played areas of remodelling. In contrast, mice receiving the anti-
CCL5 antibodies either as single-agent treatment or in combina-
tion with the mPDGFRb vaccine clearly developed much fewer
and smaller lesions than all other groups (Figure 6 E and F). In
addition, the rest of the parenchyma was comparable to that of
normal animals. At the time of sacrifice, lesions often featured
necrotic tumor cells admixed with dense infiltrates. The most
remarkable observations concerned small and medium sized
nodules showing at their periphery the presence of bands of cells
with dense round nuclei. CD45 immunostaining confirmed the
presence of immunoreactive leukocytes at the interface with the
healthy tissue and within the lesions (Figure 6 I and J) of liver
sections from the anti-CCL5- and combined regimen-treated mice
whereas considerably less CD45-positive leukocytes were detected
on liver sections from control and vaccinated animals (Figure 6 G
and H).
Discussion
In the present work, we provide the first evidence of the
implication of CCL5 in the pathophysiology of colorectal
carcinoma. CCL5 neutralization resulted in reducing the extent
of development of experimental colon tumors implanted into mice
either subcutaneously or under the liver capsule, and also led to
decrease the peritoneal carcinosis in those mice. With regard to
hepatic metastases, this result is consistent with the fact that
metastatic liver resection pieces exhibited the highest levels of
expression for CCL5, as well as for its receptors CCR1 and CCR5.
Additional evidence supporting the involvement of the CCL5/
CCR5 axis in colon cancer progression is provided by the
antitumor effect of TAK-779, the CCR5 antagonist. Proliferative
and migratory responses of the tumor cells from human and
mouse origins to CCL5 were significantly reduced by TAK-779,
thus implicating CCR5-mediated processes in the direct stimula-
tory effects of CCL5 onto CRC cells. In addition, the fact that only
partial inhibitory activity of TAK-779 against CRC cells in vitro
was observed suggested the involvement of CCR5-independent
mechanisms. Consistent with the redundancies that exist in the
chemokine family, CCL5 acts through two additional G-protein
coupled receptors termed CCR1 and CCR3 [31]. It is therefore
likely that some of the tumor-promoting properties of CCL5 in
colon cancer could be mediated through one or two of those
additional receptors. Accordingly, the protective effect of TAK-
779 against tumor development in mice was much less
pronounced than that of CCL5 blockade. In this regard, our data
contrast with those obtained in breast and pancreatic cancers
where CCR5- and CCL5-directed treatments were equally
efficient in reducing tumor progression. Collectively, our observa-
tions argue for a significant implication of CCL5 in the growth and
spread of CRC cells in vivo and in vitro, whereas CCR5 signaling
appears to be involved to a much lesser extent in the pathogenesis
of colorectal cancer.
Aside from being a promalignant factor acting directly onto
colon cancer cells, CCL5 also appeared in our studies as a
regulator of inflammatory infiltrates within tumor tissues. Indeed,
our data indicate that administration of CCL5-directed antibodies
into mice led to an accumulation of leukocytes within the cancer
stroma as well as at the interface tumor-parenchyma. In contrast
to the abundancy of inflammatory infiltrates observed in the
lesions of the anti-CCL5-treated animals, such responses were
rather poor wihin liver tumors of other treated mice, suggesting
that CCL5 blockade may favour immune destruction of the
tumor. According to a recent study by Tan et al., CCL5 is able to
induce the recruitment of regulatory T cells into pancreatic tumors
and therefore to actively induce immune tolerance [22]. With
regard to immune escape mechanisms, cancer cells exposed to
CCL5 have also been shown to induce apoptosis of CD8+ T cells
in gastric cancer [20]. The involvement of additional cell
populations in the promalignant action of CCL5 is also suggested
by our quantitative real time-PCR data performed with HT29
xenografts implanted into SCID mice. Indeed, the fact that CCR5
overexpression was observed within human CRC biopsies and
CT26 tumors using primers recognizing both tumor cells and host
cells but was not detected within human HT29 cells in vivo
indicates that CCR5 expression may originate from host cells in
the SCID model. Although SCID mice lack a functioning immune
system, they do have macrophages. In addition, stromal cells such
as fibroblasts or vascular smooth muscle cells, as well as endothelial
cells also express CCR1, CCR3 and CCR5 and may thus
participate in CCL5 promalignant action. The tumor promoting
activity of fibroblasts in colon cancer has clearly been established
[32]. As per macrophages, increasing infiltrates have been
observed with advanced stages of colorectal carcinoma [33].
However, according to the ‘‘macrophage balance hypothesis’’
described by Mantovani [34], the exact role played by
macrophages can vary from tumor suppression to promotion
depending on their number and state of activation. Therefore,
even if the aforementioned mechanisms are probably not
exclusive, it is possible that simultaneously eliciting immune
responses and compromising tumor-promoting activities through
CCL5 neutralization may account for the reduced outgrowth of
colon tumor cells in vivo.
Although, further studies will be necessary to dissect the precise
contribution of diverse factors such as the local environment or the
immune system in the tumor promoting action of CCL5, our data
clearly indicate that interfering with CCL5 signaling appears as an
attractive approach to offer protection against CRC.
Beside its potential as single agent treatment, CCL5 blockade has
recently been reported to potentiate chemotherapy. In the present
study, we have investigated whether anti-CCL5 antibodies could
potentiate a mPDGFRb-directed approach, targeting this receptor
being a strategy currently tested in the clinic (through compounds
such as Imatinib, Nilotinib or Sunitinib) for the treatment of various
oncological indications including colorectal carcinoma (melanoma,
sarcoma, breast, lung and prostate cancer [35]). Aside from
inhibitors, preclinical approaches have also been conducted to
develop PDGFRb-based DNA vaccine aiming at preventing tumor
development [36–40]. In this context, Kaplan and colleagues have
demonstrated that immunizing mice with an orally delivered
mPDGFRb-based DNA vaccine (i.e. gavage with attenuated
Salmonella typhimurium bacteria) offered significant protection against
the growth and dissemination of murine colon cancer. Here, we have
assessed the potential of a mPDGFRb encoding DNA vaccine
formulated with the amphiphilic block copolymer 704. As recently
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ability to elicit a significant immune response with 50 times less
encoding DNA than other genetic vaccination vectors but also due to
its high safety index [25,26]. In addition, immunizing mice against a
model antigen using such DNA/polymer vaccine approach was
shown to protect them against tumor challenge in an orthotopic
hepatocellular carcinoma model [25,26]. Up to now, this strategy has
however not been exploited to trigger an immune response against a
self-antigen such as PDGFRb. In the present study, we observed that
the prophylactic immunization performed to trigger PDGFRb–
specific immunotherapy in the CT26 colon cancer model only led to
a minor reduction in liver metastasis compared to control animals
thus suggesting that improvements in the vaccine protocol have to be
envisaged for its application as single agent strategy. Interestingly
however,immunizationagainstPDGFRboffered a drastic protection
when combined to anti-CCL5antibodies. Although the effect was not
total on liver metastases, only 60% of the mice developed tumorsafter
the combination regimen (vaccine plus CCL5-directed approaches),
thus supporting a cumulative effect of both strategies. Of particular
interest, 100% of the mice were also protected from peritoneal
carcinosis. In contrast, combining TAK-779 treatment with
PDGFRb vaccine failed to considerably reduce the extent of tumor
and carcinosis development compared to each treatment alone, again
supporting the greatest potential of CCL5 inhibition compared to
CCR5 antagonism in this CRC model. Previous studies from the
literature have described an up-regulation of mPDGFRb expression
within the tumor stroma of several neoplasms including colon
carcinoma [41–44] in particular on the tumor-associated pericytes
and fibroblasts [45]. Moreover, PDGFRb signaling has been shown
to stimulate recruitment of pericytes and their coverage of blood
vessels [46–48]. Accordingly, PDGFRb-directed treatments, such as
STI571 or DNA vaccines, have led to apoptosis of tumor-associated
pericytes and endothelial cells and thus to confine the vasculature to
an immature stage in colon tumors [36,37]. It is therefore possible
that simultaneous disruption of CCL5/CCRs axes potentiates this
effect on the vasculature by reducing the immune tolerance towards
tumor cells. Consistent with this hypothesis, we found increased
leukocytic infiltrateswithin lesionsofimmunized mice aftertreatment
with anti-CCL5 antibodies. In summary, our data point to a multiple
contribution of CCL5 in colon cancer development, including its
ability to promote metastatic features of tumor cells and to dampen
anti-tumor immunity. In addition, the multiplicity of promalignant
signals and of tumor-promoting cell types within colon tumors
mandates therapy combining multiple inhibitions directed against
both cancer and stromal cells to produce an effective therapy of the
neoplasm.
Taken together, our findings show that interfering with CCL5
signaling may be an approach to control the progression of this
malignancy, alone or in combination with mPDGFRb-directed
therapies.
Supporting Information
Table S1 DCT: CT(target) – CT(actin); Fold: fold change
in mRNA expression between tumor and healthy tissues;
P: p values considered significant when P,0.05.
(PPT)
Figure 6. Liver histology at the time of sacrifice. (A–F) Liver
histology was compared on sections of organs from CT26-challenged
mice either untreated (A), or immunized with mPDGFRb vaccine (B), or
treated with TAK-779 (C), with TAK-779 plus mPDGFRb vaccine (D), with
anti-CCL5 antibodies (E) or with anti-CCL5 antibodies plus mPDGFRb
vaccine (F). T=liver tumors produced by CT26 cells; N=area of necrosis
in a liver tumor; H=hepatocytes; Arrows indicate the presence of dense
infiltrates at the interface with the healthy tissue and within lesions.
(G–J) CD45-staining reveals immunoreactive leukocytes at the interface
tumor-parenchyma and within hepatic lesions of anti-CCL5- (I) and anti-
CCL5/PDGFRb-treated mice (J) but less leukocytes within vaccinated
mice (H) and almost no staining in untreated mice (G).
doi:10.1371/journal.pone.0028842.g006
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